🧫
In vitro T-cell killing assay with OVA-presenting tumor cells
active
experiment
Created: 2026-04-10T14:35:17
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-fa85731c-e419-4753-8722-d561dd0ce083
🧫 Experiment Protocol
ExploratorycancerNPM1OVA-presenting tumor cells and OT-1 transgenic T cellsproposed
Assessment of antigen-specific T-cell mediated killing of tumor cells presenting ovalbumin (OVA) by OT-1 transgenic T cells. This experiment evaluated how NPM1 deficiency affects the ability of tumor cells to present antigens and be recognized and killed by specific cytotoxic T lymphocytes. The study demonstrated that Npm1 deficiency increased MHC-I and MHC-II molecule expression and enhanced specific T-cell killing capacity.
PRIMARY OUTCOME
T-cell mediated tumor cell killing efficiency
EXPECTED OUTCOMES
NPM1 deficiency would enhance T-cell recognition and killing of tumor cells
SUCCESS CRITERIA
Increased cytotoxic T lymphocyte-mediated tumor cell death
PROTOCOL
In vitro co-culture of OVA-presenting tumor cells with OT-1 transgenic T cells to measure antigen-specific cytotoxicity
LINKED HYPOTHESES
Source: PMID 39402629 ↗
🧫 Experiment Extras
PATHWAY
antigen presentation pathway, MHC-I presentation
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.